Medical/Pharmaceuticals
Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecifi...
2024-11-28 21:06
2606
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...
2024-11-28 17:22
2028
New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List
ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...
2024-11-28 16:59
2059
Own Your Story with AwarerHOME™
Malaysia's HIV Oral Self-Test for Accessible and Confident Testing KUALA LUMPUR, Malaysia, Nov. 28, 2024 /PRNewswire/ -- Say hello to confidence and control with AwarerHOME™,Malaysia's first homegrown HIV Oral Self-Test. This accessible, no-mess, no-fuss solution offers something even more impor...
2024-11-28 16:34
1532
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List
SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...
2024-11-28 13:43
1751
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country
SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...
2024-11-28 13:04
1866
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-11-28 12:07
2146
Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab
HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...
2024-11-28 11:58
1777
Newbase Launches 'Medicrew', a VR Medical Training Platform to Accelerate Global Market Expansion
Participation in IMSH 2025 to Showcase Innovations in Medical Education
SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Newbase
2024-11-28 09:00
1622
Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging
* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announc...
2024-11-27 22:00
1601
Prenetics Announces Third Quarter 2024 Financial Results
Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 /P...
2024-11-27 21:30
2616
Award-Winning CMUH (Taiwan) Excels at HIMSS, Leading Taiwan's Smart Healthcare Transformation
TAICHUNG, Nov. 27, 2024 /PRNewswire/ -- In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, China Medical University Hospital (CMUH) established international presence with four notable gradings: achieving the top score in the 2023 HIMSS Global Digital Health Indicator (DHI) and receiving ...
2024-11-27 21:00
1499
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy
SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...
2024-11-27 19:08
2664
Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC
CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...
2024-11-27 14:34
1982
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...
2024-11-27 14:00
1570
8 in 10 say a healthier diet is important to support mental and physical health - Herbalife Asia Pacific survey
HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Herbalife, a premier health and wellness company and community, today released findings from itsAsia Pacific "New Year, New Me" survey,which revealed that 85% of consumers say a healthier diet is important to support their mental and physical health. Almos...
2024-11-27 11:00
1853
VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation
GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...
2024-11-26 22:00
1842
IMG Releases 2024 Holiday Travel Trends
* IMG has reviewed a sample of member data including more than 17,000 travel itineraries of travelers with upcoming travel plans between Thanksgiving Day and New Year's Day to determine emerging travel trends this holiday season. INDIANAPOLIS, Nov. 26, 2024 /PRNewswire/ -- IMG (International Me...
2024-11-26 22:00
1312
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...
2024-11-26 18:49
8640
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)
* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...
2024-11-26 17:16
1742
Week's Top Stories
Most Reposted
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 281 media titles]
2024-12-30 15:33
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
[Picked up by 277 media titles]
2025-01-03 19:33
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 276 media titles]
2025-01-02 08:16
CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 258 media titles]
2024-12-31 22:30Most Read
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
2024-12-30 15:33
8705
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
2024-12-31 14:18
8703